INVESTED Study:
Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated HF
Inclusion: hospitalization for CHF within past 2 years or myocardial infarction within the past 1 year
Sponsor: NHLBI/ NIH.
To refer a patient to this study please contact Gregory Pontone, MD/ Jackson Ng/ @ [email protected]
XIENCE Study:
Short DAPT in subjects at high risk of bleeding undergoing PCI with XIENCE
Adults at high bleeding risk defined as: Age >75, indication for chronic anti-coagulation, history of stroke, history of major bleed within 12 months, Creat >2 or ESRD, Hgb<11, or systemic conditions associated with increased bleeding risk.
Angiographic criteria are specific, but basically isolating low risk lesions up to 32 mm length. Several exclusion criteria but main ones are: STEMI, EF less than 30%, planned surgery, SVG or CTO lesion, lesion is a prior stent restenosis, unwilling to stop P2Y12 inhibitor at 90 days.
Sponsor: Abbott Cardiovascular Systems.
To refer a patient to this study please contact Emmanuel Moustakakis, MD/ Jackson Ng/ @ [email protected]
PARADISE Study:
Efficacy and safety of LCZ696 compared to Ramipril on morbidity and mortality in high risk patients following an acute MI
Prospective ARNI versus ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction- A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 (entrust) compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
Sponsor: Novartis Pharmaceuticals Corp.
To refer a patient to this study please contact Emmanuel Moustakakis, MD/ Jackson Ng/ @ [email protected]
PARAGON Study:
Efficacy and safety of LCZ696 compared to Valsartan, on morbidity and mortality in HF patients (NYHA Class II-IV) with preserved EF
Sponsor: Novartis Pharmaceuticals Corp.
To refer a patient to this study please contact Daniel Lorber, MD/ Jackson Ng/ @ [email protected]
ABSORB Study:
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions
Sponsor: Abbott Cardiovascular Systems, Inc.
To refer a patient to this study please contact Emmanuel Moustakakis, MD/ Jackson Ng/ @ [email protected]
TACT 2 Study:
Edetate disodium-based IV chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior MI
TACT2 will examine the use of intravenous chelation treatments in combination with oral vitamins in diabetic patients with a prior heart attack to determine if they reduce recurrent heart episodes, such as heart attacks, stroke, death, and others, by removing toxins from the blood.
Sponsor: National Institutes of Health.
To refer a patient to this study please contact Daniel Lorber, MD/ Mari Tsovian/ @ [email protected]
PROMINENT Study:
PEMAFIBRATE to reduce cardiovascular outcomes by reducing TGs in patients with DM
The primary scientific aim of the PROMINENT study is to assess whether treatment with the selective peroxisome proliferator activated receptor modulator alpha (SPPARM-α), pemafibrate, will prevent myocardial infarction (MI), ischemic stroke, unstable angina requiring unplanned revascularization, and cardiovascular (CV) death in adults with type 2 diabetes (T2D) who have elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels and are at high risk for future CV events.
Sponsor: Kowa Research Inst., Inc.
To refer a patient to this study please contact Daniel Lorber, MD/ Mari Tsovian/ @ mat[email protected]
MINT Study:
Myocardial Ischemia and Transfusion
Sponsor: NIH/ Rutgers.
To refer a patient to this study please contact Xuming Dai, MD/ Ajini Cherian & Asif Adam/ @ [email protected]
QP Excel Study:
Sentus QP - Extended CRT Evaluation with Quadripolar Left Ventricular Leads
Sponsor: BIOTRONIK, Inc.
To refer a patient to this study please contact Seth H. Goldbarg, MD/ Jackson Ng/ @ [email protected]
For Weill Cornell Medicine and New York-Presbyterian collaboration to advance clinical research
Click here to learn more about their clinical trials.